JP2024037765A5 - - Google Patents

Download PDF

Info

Publication number
JP2024037765A5
JP2024037765A5 JP2023202413A JP2023202413A JP2024037765A5 JP 2024037765 A5 JP2024037765 A5 JP 2024037765A5 JP 2023202413 A JP2023202413 A JP 2023202413A JP 2023202413 A JP2023202413 A JP 2023202413A JP 2024037765 A5 JP2024037765 A5 JP 2024037765A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023202413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024037765A (ja
Filing date
Publication date
Priority claimed from GBGB1800649.4A external-priority patent/GB201800649D0/en
Application filed filed Critical
Publication of JP2024037765A publication Critical patent/JP2024037765A/ja
Publication of JP2024037765A5 publication Critical patent/JP2024037765A5/ja
Pending legal-status Critical Current

Links

JP2023202413A 2018-01-16 2023-11-30 Cd70組合せ療法 Pending JP2024037765A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1800649.4A GB201800649D0 (en) 2018-01-16 2018-01-16 CD70 Combination Therapy
GB1800649.4 2018-01-16
PCT/EP2019/051058 WO2019141732A1 (en) 2018-01-16 2019-01-16 Cd70 combination therapy
JP2020559030A JP7511479B2 (ja) 2018-01-16 2019-01-16 Cd70組合せ療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020559030A Division JP7511479B2 (ja) 2018-01-16 2019-01-16 Cd70組合せ療法

Publications (2)

Publication Number Publication Date
JP2024037765A JP2024037765A (ja) 2024-03-19
JP2024037765A5 true JP2024037765A5 (enExample) 2024-06-27

Family

ID=61256176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559030A Active JP7511479B2 (ja) 2018-01-16 2019-01-16 Cd70組合せ療法
JP2023202413A Pending JP2024037765A (ja) 2018-01-16 2023-11-30 Cd70組合せ療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020559030A Active JP7511479B2 (ja) 2018-01-16 2019-01-16 Cd70組合せ療法

Country Status (22)

Country Link
US (2) US11530271B2 (enExample)
EP (2) EP4275702A3 (enExample)
JP (2) JP7511479B2 (enExample)
KR (1) KR102790232B1 (enExample)
CN (1) CN111836830B (enExample)
AU (1) AU2019209503B2 (enExample)
BR (1) BR112020014321A2 (enExample)
CA (1) CA3086448A1 (enExample)
DK (1) DK3740504T5 (enExample)
EA (1) EA202091714A1 (enExample)
ES (1) ES2956258T3 (enExample)
FI (1) FI3740504T3 (enExample)
GB (1) GB201800649D0 (enExample)
HU (1) HUE063783T2 (enExample)
IL (1) IL276103A (enExample)
LT (1) LT3740504T (enExample)
MX (1) MX2020007606A (enExample)
PL (1) PL3740504T3 (enExample)
PT (1) PT3740504T (enExample)
SG (1) SG11202006007YA (enExample)
WO (1) WO2019141732A1 (enExample)
ZA (1) ZA202003986B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン, インコーポレイテッド 抗-il1rap抗体および抗体薬物コンジュゲート
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
US20220306737A1 (en) * 2019-09-16 2022-09-29 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
MX2022008763A (es) * 2020-01-17 2022-07-27 Novartis Ag Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
US20240252641A1 (en) * 2020-05-05 2024-08-01 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
EP4232052A4 (en) * 2020-10-22 2025-08-20 Actinium Pharmaceuticals Inc COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
CN114765061B (zh) * 2021-01-15 2024-12-27 深圳哲源生物科技有限责任公司 Pd-1/pd-l1抑制剂的不良预后的数据处理系统及方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
AU2022304582A1 (en) * 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004223837C1 (en) 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
KR20080056167A (ko) 2005-09-26 2008-06-20 메다렉스, 인코포레이티드 씨디70에 대한 인간 모노크로날 항체
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Cd70に結合するヒト抗体およびその使用
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
WO2010117057A1 (ja) 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
PL2464232T3 (pl) 2009-08-10 2016-04-29 Samumed Llc Indazolowe inhibitory szlaku sygnałowego Wnt i ich zastosowania terapeutyczne
WO2011035433A1 (en) 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
PH12012500924A1 (en) 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra
CA2785964C (en) 2009-12-29 2021-03-30 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
CN104379583B (zh) 2012-06-15 2016-06-08 广州源生医药科技有限公司 作为wnt信号传导抑制剂的化合物、组合物及其应用
IN2015DN00140A (enExample) 2012-08-31 2015-06-12 Argen X Bv
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Cd70及cd3抗體構築體
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
SMT202200118T1 (it) * 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
US20220136068A1 (en) 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
EP4204098A1 (en) 2020-08-29 2023-07-05 Argenx BV Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
EP4225949A1 (en) 2020-10-06 2023-08-16 The Regents of the University of Colorado, a body corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia

Similar Documents

Publication Publication Date Title
JP2023113641A5 (enExample)
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2026012786A5 (enExample)
JP2024037765A5 (enExample)
JP2024063016A5 (enExample)
JP2023113681A5 (enExample)
JP2025023938A5 (enExample)
JP2023164986A5 (enExample)
JP2023153863A5 (enExample)
JP2025106258A5 (enExample)
JP2023134519A5 (enExample)
JP2023103231A5 (enExample)
JP2024156705A5 (enExample)
JP2025118771A5 (enExample)
JP2025038009A5 (enExample)
JP2024088648A5 (enExample)
JP2023139025A5 (enExample)
JP2018100276A5 (enExample)
JP2025143267A5 (enExample)
JP2024160274A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2024038101A5 (enExample)
JP2023100679A5 (enExample)